Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 3 3Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Recruiting 5Withdrawn 2Unknown 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Xerostomia Due to Radiotherapy (Disorder) 12019 Novel Coronavirus 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Standard of Care × Clear all
NCT04731051 2023-04-07

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients

King Hussein Cancer Center

Phase 1/2 Withdrawn

2019 Novel Coronavirus

NCT03061110 2018-04-30

Stromal Vascular Fraction for Treatment of Xerostomia

Midwestern Regional Medical Center

Phase 1/2 Withdrawn

Xerostomia Due to Radiotherapy (Disorder)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡